



NSGO Annual Meeting 2022

Helsinki

March 31 – April 1, 2022

Topic: Ovarian Cancer

Venue: Hilton Helsinki Kalastajatorppa

Kalastajatorpantie 1

00330 Helsinki

Wednesday March 30, 2022		
16.30-17.30 (Keltainen Sali)	NSGO Foundation (Closed meeting)	
17.30-18.45 (Keltainen Sali)	NSGO Board meeting (Closed meeting)	
19.00-21.00 (Dinner: 19.00-19.30 Siirtomaasali I) (Symposium: 19.30-21.00 Siirtomaasali I)	Dinner and NSGO-symposium - with educational grants from MSD & Eisai Role of Immunotherapy in Relapsed Endometrial Cancer <ol style="list-style-type: none">1. Molecular classification of endometrial cancer: is it necessary?2. Role of Immunotherapy in relapsed disease3. Managing the toxicity of novel agents4. Discussion	A Auranen & K Lindemann (Chairs) I McNeish J Sehouli A Gonzales Martin

Thursday March 31, 2022		
08.00-09.30 NSGO-CTU SC (Keltainen Sali)	NSGO-CTU SC Meeting (Closed meeting)	
(Radiotherapy: Kapteeni)	Workshops: NSGO Radiotherapy Group (Closed meeting)	
(Media Group: Admiraali)	Workshops: NSGO Media Group (Closed meeting)	
09.45-10.00 (Siirtomaasali I)	Opening statement by the NSGO president	L Bjørge
10.00-11.30 (Siirtomaasali I)	<u>Topic:</u> Early detection and diagnosis <ul style="list-style-type: none">○ Epidemiology and prevention○ Screening and early detection: Standard of care and beyond standard○ Diagnostics: Standard of care and beyond standard Discussion	TJ Nøttrup (chair) RT Fortner U Menon (Virtual) D Fischerova
11.30-12.00 (Siirtomaasali II)	Break & Exhibition	
12.00-13.00 (Siirtomaasali I)	<u>Topic:</u> Surgery <ul style="list-style-type: none">○ Standard of care○ Beyond standard and re-thinking Discussion	L Bjørge (chair) A du Bois C Fotopoulou
13.00-14.00	Lunch	

(Pyöreä Sali)		
13.00-14.00 (Hilton Matruusi)	Workshops: NSGO TR Group (Closed meeting)	
14.00-15.45 (Siirtomaasali I)	Investigator meeting	MR Mirza (chair)
15.45-16.00 (Siirtomaasali II)	Break & Exhibition	
16.00-18.00 (Siirtomaasali I)	<p>NSGO-symposium- with educational grants from AstraZeneca</p> <p>Real World Characterization of First-line Ovarian Cancer</p> <ol style="list-style-type: none"> 1. Introduction 2. Treatment decisions with the available options 3. Molecular classification to guide targeted therapy 4. Molecular testing (BRCA, HRD ...) – the Nordic initiative 5. How can we use Real World data to guide the treatment? 6. Discussion 	<p>L Bjørge & I Vergote (chairs)</p> <p>I Vergote</p> <p>A du Bois</p> <p>I McNeish</p> <p>A Farkkila</p> <p>C Fotopoulou</p>
18.00-18.03 (Siirtomaasali I)	Introduction of ESGO President Nicole Concin	L Bjørge
18.03-18.15 (Siirtomaasali I)	ESGO improving the care of our patients	N Concin (Virtual)
18.15-19.30 (Siirtomaasali I)	Scientific presentations	L Bjørge (chair)
20.00-20.30 Lobby	Welcome drink	
20.30 – (Pyöreä Sali)	Dinner	

Friday April 1, 2022		
08.00-09.00 (Siirtomaasali I)	General assembly (Closed meeting)	
09.00-09.30 (Siirtomaasali I)	Lecture: New treatment algorithm	MR Mirza
09.30-11.00 (Siirtomaasali I)	<u>Topic:</u> Chemotherapy and targeted therapeutics – Front line ○ Standard of care ○ Beyond standard ○ Re-thinking Discussion	H Dahlstrand (chair) S Pignata (Virtual) A González Martín I McNeish
11.00-12.00 (Siirtomaasali I)	<u>Topic:</u> Chemotherapy and targeted therapeutics – Recurrence ○ Standard and beyond standard ○ Rethinking Discussion	A Färkkilä (chair) K Lorusso F Marmé
12.00 -12.15 (Siirtomaasali II)	Break & Exhibition	
12:15-13.45 (Siirtomaasali I)	NSGO-symposium - with educational grants from GSK Maintenance PARP inhibitor therapy in Ovarian Cancer 1. Maintenance therapy: available options 2. Shall all patients receive PARP inhibitor maintenance in first-line a. Pro all patients in first-line b. Pro sequencing the two options (PARPi, Bevacizumab) 3. What are the treatment options for patients progressed on/after PARP inhibitors? Discussion	MR Mirza & H Dahlstrand (chairs) S Pignata (Virtual) K Lorusso A Gonzales Martin F Marmé
13.45-14.30 (Pyöreä Sali)	Lunch	
14.30-14.45 (Siirtomaasali II)	Coffee & Exhibition	
14.45-15.45 (Siirtomaasali I)	<u>Topic:</u> Survivorship ○ Clinical outcomes after completing treatment ○ Ethical and social aspects of emerging science and technology Discussion	K Lindemann (chair) J. Sehouli R Strand
15.45-16.00 (Siirtomaasali I)	Welcome to NSGO Annual Meeting 2023 meeting - Iceland	K Kristjánsdóttir and Á Thoroddsen
16.00-16.30 (Keltainen Sali)	NSGO Constitutional Board (Closed meeting)	



Gold Sponsors of NSGO Annual Meeting 2022



Exhibitors of NSGO Annual Meeting 2022

